A Study Aimed at Assessing the Pharmacokinetic Properties of RGB-10 and Forsteo

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

Pharmacokinetic properties, safety and tolerability of RGB-10 and Forsteo will be compared in healthy female volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Gedeon Richter Plc.
• Treatments: Teriparatide

Criteria

Inclusion Criteria:

• Healthy adult female subjects

• 18-55 years of age (inclusive)

• BMI must be between 18.5 and 27 kg/m2 (inclusive)

Exclusion Criteria: